LOAMU
ACAD icon

Lombard Odier Asset Management (USA)’s Acadia Pharmaceuticals ACAD Stock Holding History

Lombard Odier Asset Management (USA)’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-497
Closed -$1.39M – 209
2016
Q1 		$1.39M Buy
+497
New +$10.8K 0.19% 117

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 17.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Lombard Odier Asset Management (USA)'s ACAD Position: Q3 2016 in Review

Lombard Odier Asset Management (USA) sold out of Acadia Pharmaceuticals (ACAD) in Q3 2016, closing a stake of 75,000 shares — an estimated $2.44M sold.

Lombard Odier Asset Management (USA) first reported a position in ACAD in Q2 2013 and held it in 9 quarters. The position peaked at $5.57M in Q3 2014. 233 funds tracked by Wall St. Rank hold ACAD as of Q3 2016.

  • Lombard Odier Asset Management (USA) reported no remaining Acadia Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Lombard Odier Asset Management (USA) sold 75,000 Acadia Pharmaceuticals shares in Q3 2016, an estimated $2.44M.
  • Lombard Odier Asset Management (USA) first reported a position in Acadia Pharmaceuticals in Q2 2013 and held it in 9 quarters.
  • Lombard Odier Asset Management (USA)'s Acadia Pharmaceuticals position peaked at $5.57M in Q3 2014.
  • 233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2016.

Based on Lombard Odier Asset Management (USA)'s 13F filing for Q3 2016, filed 15 Nov 2016.